Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2019 Jun 4;8(11):e012514.
doi: 10.1161/JAHA.119.012514. Epub 2019 Jun 1.

Role of Targeted Therapy in Dilated Cardiomyopathy: The Challenging Road Toward a Personalized Approach

Job A J Verdonschot  1   2 , Mark R Hazebroek  1 , James S Ware  3   4   5 , Sanjay K Prasad  3   4 , Stephane R B Heymans  1   6   7
Affiliations
Review

Role of Targeted Therapy in Dilated Cardiomyopathy: The Challenging Road Toward a Personalized Approach

Job A J Verdonschot et al. J Am Heart Assoc. .
No abstract available

Keywords: dilated cardiomyopathy; personalized; phenotyping; therapy.

PubMed Disclaimer

Figures

Figure 1
Figure 1
Different upstream environmental triggers on an individual genetic background can lead to dilated cardiomyopathy. DCM indicates dilated cardiomyopathy characterized by dilatation of the left and/or right ventricle and reduced cardiac function in the absence of ischemia and/or hemodynamic stress.
Figure 2
Figure 2
Complete diagnostic workup of a dilated cardiomyopathy patient to characterize the cardiac function and underlying cause. CRP indicates C‐reactive protein; sIL2‐R, soluble interleukin 2 receptor.
Figure 3
Figure 3
Two examples of genetic mutations leading to dilated cardiomyopathy and their potential treatment targets interfering with disease progression at different levels.
See this image and copyright information in PMC

References

    1. Japp AG, Gulati A, Cook SA, Cowie MR, Prasad SK. The diagnosis and evaluation of dilated cardiomyopathy. J Am Coll Cardiol. 2016;67:2996–3010. - PubMed
    1. Hazebroek MR, Moors S, Dennert R, van den Wijngaard A, Krapels I, Hoos M, Verdonschot J, Merken JJ, de Vries B, Wolffs PF, Crijns HJ, Brunner‐La Rocca HP, Heymans S. Prognostic relevance of gene‐environment interactions in patients with dilated cardiomyopathy: applying the MOGE(S) classification. J Am Coll Cardiol. 2015;66:1313–1323. - PubMed
    1. Writing Committee M , Yancy CW, Jessup M, Bozkurt B, Butler J, Casey DE Jr, Drazner MH, Fonarow GC, Geraci SA, Horwich T, Januzzi JL, Johnson MR, Kasper EK, Levy WC, Masoudi FA, McBride PE, McMurray JJ, Mitchell JE, Peterson PN, Riegel B, Sam F, Stevenson LW, Tang WH, Tsai EJ, Wilkoff BL; American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines . 2013 ACCF/AHA guideline for the management of heart failure: a report of the American College of Cardiology Foundation/American Heart Association Task Force on practice guidelines. Circulation. 2013;128:e240–e327. - PubMed
    1. Pao W, Fodor I. Catalyzing the field of precision oncology, one basket at a time. Nat Med. 2018;24:387–388. - PubMed
    1. Verdonschot J, Hazebroek M, Merken J, Debing Y, Dennert R, Brunner‐La Rocca HP, Heymans S. Relevance of cardiac parvovirus B19 in myocarditis and dilated cardiomyopathy: review of the literature. Eur J Heart Fail. 2016;18:1430–1441. - PubMed

Publication types

Substances